JP2001520238A5 - - Google Patents

Download PDF

Info

Publication number
JP2001520238A5
JP2001520238A5 JP2000516991A JP2000516991A JP2001520238A5 JP 2001520238 A5 JP2001520238 A5 JP 2001520238A5 JP 2000516991 A JP2000516991 A JP 2000516991A JP 2000516991 A JP2000516991 A JP 2000516991A JP 2001520238 A5 JP2001520238 A5 JP 2001520238A5
Authority
JP
Japan
Prior art keywords
amino acid
ifnα
analog
polypeptide analog
natural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000516991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001520238A (ja
Filing date
Publication date
Priority claimed from US08/954,395 external-priority patent/US6204022B1/en
Application filed filed Critical
Publication of JP2001520238A publication Critical patent/JP2001520238A/ja
Publication of JP2001520238A5 publication Critical patent/JP2001520238A5/ja
Pending legal-status Critical Current

Links

JP2000516991A 1997-10-20 1998-10-20 低毒性のヒトインターフェロン−αアナログ Pending JP2001520238A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/954,395 US6204022B1 (en) 1996-04-12 1997-10-20 Low-toxicity human interferon-alpha analogs
US08/954,395 1997-10-20
PCT/US1998/021936 WO1999020653A1 (en) 1997-10-20 1998-10-20 Low-toxicity human interferon-alpha analog

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008161051A Division JP2008247926A (ja) 1997-10-20 2008-06-19 低毒性のヒトインターフェロン−αアナログ

Publications (2)

Publication Number Publication Date
JP2001520238A JP2001520238A (ja) 2001-10-30
JP2001520238A5 true JP2001520238A5 (https=) 2005-06-23

Family

ID=25495373

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000516991A Pending JP2001520238A (ja) 1997-10-20 1998-10-20 低毒性のヒトインターフェロン−αアナログ
JP2008161051A Pending JP2008247926A (ja) 1997-10-20 2008-06-19 低毒性のヒトインターフェロン−αアナログ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008161051A Pending JP2008247926A (ja) 1997-10-20 2008-06-19 低毒性のヒトインターフェロン−αアナログ

Country Status (13)

Country Link
US (1) US6204022B1 (https=)
EP (1) EP1025124B1 (https=)
JP (2) JP2001520238A (https=)
KR (2) KR100586625B1 (https=)
CN (1) CN1240717C (https=)
AT (1) ATE402957T1 (https=)
AU (1) AU744774B2 (https=)
CA (1) CA2308116C (https=)
DE (1) DE69839812D1 (https=)
DK (1) DK1025124T3 (https=)
ES (1) ES2310931T3 (https=)
TW (1) TW593336B (https=)
WO (1) WO1999020653A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833256B1 (en) * 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
AU781377B2 (en) * 1999-08-27 2005-05-19 University Of Florida Research Foundation, Inc. Materials and methods for inhibition of IgE production
EP2213743A1 (en) * 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
IL155730A0 (en) * 2000-11-03 2003-11-23 Biomedicines Inc Method for short-term and long-term drug dosimetry
WO2002045737A2 (en) * 2000-12-07 2002-06-13 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
KR20040022244A (ko) 2001-08-12 2004-03-11 펩젠 코포레이션 하이브리드 인터페론/인터페론 타우 단백질, 조성물 및사용방법
CA2466228A1 (en) * 2001-11-09 2003-08-07 Biomedicines, Inc. Method for treating diseases with omega interferon
AU2003228267A1 (en) * 2002-03-05 2003-09-22 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US20040126360A1 (en) * 2002-10-09 2004-07-01 Manning Mark C. Oral formulations for proteins and polypeptides
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CN102836420B (zh) * 2003-03-03 2014-03-12 得克萨斯州大学系统董事会 包含mda-7的组合物和方法
US20050003533A1 (en) 2003-05-08 2005-01-06 Pawel Kalinski Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use
WO2005082396A2 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
BRPI0507169A (pt) * 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
AU2006211960A1 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
US7695710B2 (en) * 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
CA2612901A1 (en) * 2005-06-20 2007-01-04 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
RU2288474C1 (ru) * 2005-12-28 2006-11-27 Федеральное государственное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии имени Г.Н. Габричевского Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" (ФГУН МНИИЭМ им. Г.Н. Габричевского Роспотребнадзора) Способ определения токсического действия оральной мукозальной интерферонотерапии
US20070243163A1 (en) * 2006-02-17 2007-10-18 Chih-Ping Liu Respiratory tract delivery of interferon-tau
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
WO2008121461A2 (en) * 2007-02-26 2008-10-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vaccine for activating helper function of cd8+ tcells
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
MX344166B (es) 2008-02-08 2016-12-07 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2440251A4 (en) 2009-06-09 2013-01-16 Defyrus Inc INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012177892A2 (en) * 2011-06-21 2012-12-27 University Of Florida Research Foundation, Inc. Type i interferon mimetics as therapeutics for cancer, viral infections, and multiple sclerosis
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2730996C2 (ru) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Системы установки и извлечения имплантата
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス,インコーポレイティド Glp-1受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
CN112043685A (zh) * 2020-09-18 2020-12-08 深圳科兴药业有限公司 重组人干扰素α1b突变体吸入溶液及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016015B (en) 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
US4460574A (en) 1980-06-16 1984-07-17 Yabrov Alexander A Prophylaxis or treatment of interferon-sensitive diseases
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4414150A (en) 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4507281A (en) 1981-10-13 1985-03-26 Exovir, Inc. Interferon-containing compositions
WO1983002461A1 (en) 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP0146903A3 (en) 1983-12-19 1987-07-22 Schering Corporation Production of a vector encoding a novel hybrid interferon species
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
US4636383A (en) 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
DE3607835A1 (de) 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
US4846782A (en) 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
EP0240224A3 (en) 1986-03-31 1989-02-01 Interferon Sciences, Inc. An alpha interferon analogue
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
TW391983B (en) 1992-10-30 2000-06-01 Univ Florida Human interferon TAU, processes thereof and pharmaceutical uses thereof
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them

Similar Documents

Publication Publication Date Title
JP2001520238A5 (https=)
ES2310931T3 (es) Analogos de interferon alfa humano de baja toxicidad.
US5676942A (en) Composition containing human alpha interferon species proteins and method for use thereof
JP6325585B2 (ja) インターロイキン−22のウイルス性肝炎の治療における応用
KR950014915B1 (ko) 탈시알로당단백-포함화합물
PL176408B1 (pl) Kompozycja naturalnego alfa interferonu z ludzkich leukocytów krwi obwodowej i sposób wytwarzania kompozycji naturalnego alfa interferonu z ludzkich leukocytów krwi obwodowej
RU95113418A (ru) Полипептиды, способы получения, днк, вектор, клетка, применение полипептида, фармацевтические композиции
JP4617058B2 (ja) コンセンサスインターフェロンのB型肝炎表面抗原とe抗原の抑制剤としての応用
RU2006145020A (ru) Полипептиды и конъюгаты интерферона-альфа
WO2005046569A2 (en) Pharmaceutical compositions for the treatment of sars
JPH0749440B2 (ja) インターフェロン アルファー2結晶の製造方法
JPH0653676B2 (ja) インターフェロンの相乗効果
MX2009001366A (es) Proteinas semejantes a interferon humano recombinante.
CA2311648A1 (en) Ifnar2/ifn complex
JP2000511762A (ja) ケラチノサイト増殖因子アナログ
Pontzer et al. Structure/function studies with interferon tau: evidence for multiple active sites
JP2005525784A5 (https=)
JP5209462B2 (ja) コンセンサスインターフェロンの使用方法
CN101671390B (zh) 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
JPH10330284A (ja) 肝細胞保護剤
TW200800247A (en) Method of treatment using interferon-τ
AU2003240758B2 (en) Chemokines mutants having improved oral bioavailability
AU2005221710A1 (en) Pharmaceutical compositions comprising interferon-tau
JPH10330283A (ja) 消化管組織再生賦活剤
JP3002213B2 (ja) ペプチドおよびこのペプチドを含有する薬剤